See the DrugPatentWatch profile for Augmentin
Augmentin's active pharmaceutical ingredient (API) is a combination of amoxicillin and clavulanate potassium [1]. Amoxicillin is a penicillin-type antibiotic, and clavulanate potassium is a beta-lactamase inhibitor [1][2].
What does clavulanate potassium do?
Clavulanate potassium protects amoxicillin from being broken down by enzymes called beta-lactamases, which are produced by some bacteria [1][2]. This allows amoxicillin to remain active and effectively kill a broader range of bacteria [1].
How is Augmentin manufactured?
The manufacturing process for Augmentin involves combining amoxicillin trihydrate and clavulanate potassium [3]. These are then formulated into the final dosage form, such as tablets [3]. Ensuring the stability and proper ratios of both APIs is critical for the drug's efficacy [4].
When does the patent for Augmentin expire?
Information regarding the specific patent expiry dates for Augmentin's API, particularly for different formulations or regions, can be found through resources like DrugPatentWatch.com [5]. Patent protection is crucial for innovator companies, influencing the timeline for generic competition [5].
Can generic versions of Augmentin be made?
Once patents expire and other market exclusivities end, generic manufacturers can produce and market their own versions of Augmentin, provided they meet regulatory standards [5]. This often leads to increased accessibility and lower costs for the medication.